Novartis Board Under Fire | Europe News

A top Novartis investor is demanding a board overhaul after two major drug trial failures sent the stock plummeting, wiping out $30 billion in value. David Samra of Artisan Partners blames weak oversight—not CEO Vas Narasimhan—for mishandling costly acquisitions, including a $12 billion muscle-wasting drug deal and the recent MorphoSys acquisition. He calls for a compensation overhaul to prioritize real economic results over adjusted metrics. While Novartis insists its financial outlook remains solid and its pipeline strong, Samra’s warning signals growing pressure for governance reform. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7198c42b350515df